EC DECLARATION OF CONFORMITY

with the participation of Notified body No. 1023 INSTITUT PRO TESTOVÁNÍ A CERTIFIKACI, a. s. třída Tomáše Bati 299, Louky 763 02 Zlín - diagnostic medical devices *in vitro*

Pursuant to Section 13(2) of Act No 22/1997 Coll., on the Technical Requirements for Products, and on a change and addition to certain laws, as amended, and pursuant to Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on *in vitro* diagnostic medical devices, the requirements of which have been adopted by Government Regulation 56/2015 Coll., on Technical Requirements for *in vitro* Diagnostic Medical Devices, as amended, and under Commission Decision 2002/364/EC of 7 May 2002 on common technical specifications for *in vitro* diagnostic medical devices, as amended

MANUFACTURER

GeneProof a.s., Vídeňská 101/119, Dolní Heršpice, 619 00 Brno, Czech Republic
www.geneproof.com

hereby declares that following product

GeneProof Hepatitis C Virus (HCV) Diagnostic PCR Kit

Medical device type:	***in vitro* diagnostic medical device**
Classification:	**List A, Annex II**
Intended purpose of the device:	**kit is intended for qualitative and quantitative diagnostics, aid to diagnostics or monitoring of Hepatitis C virus (HCV) from plasma or serum by the real-time Polymerase Chain Reaction (PCR) method. The intended users are professional personnel of clinical laboratories.**
Variants:	**HCVD/ISEX/025, HCVD/ISEX/100**

complies with the basic requirements of Annex No. 1 of the Directive 98/79/EC of the European Parliament and of the Council and the Czech Government Regulation No. 56/2015 Coll. and under normal use it is safe and effective for its intended purpose. The manufacturer has taken measures assuring compliance of all medical agents introduced into the market with their technical documentation and with the essential requirements.

Following currently valid version of the standards were applied to meet essential requirements:

ČSN EN ISO 13485 ed.2:2016	Medical device – QMS – Requirements for regulatory purposes
ČSN EN ISO 14971:2020	Medical device – QMS – Application of risk management to medical devices
ČSN EN ISO 18113-1:2012	In vitro diagnostic medical devices -- Information supplied by the manufacturer (labelling) -- Part 1 Terms, definitions and general requirements
ČSN EN ISO 18113-2:2012	In vitro diagnostic medical devices -- Information supplied by the manufacturer (labelling) -- Part 2 In vitro diagnostic reagents for professional use
ČSN EN ISO 15223-1:2017	Medical devices – Symbols to be used with medical device labels, labelling and information to be supplied, Part1: General requirements
ČSN EN ISO 23640:2016	In vitro diagnostic medical devices – Evaluation of stability of in vitro diagnostic reagents

Procedure described in Annex No. 4 of the Directive 98/79/EC of the European Parliament and of the Council and the Czech Government Regulation No. 56/2015 Coll. was used to evaluate the basic characteristics of the product by the designated method and conformity is confirmed by Full Quality Assurance System certificate No. 140005 QS/NB, revision (i), with validity till January 17, 2024 and Design Examination certificate No. 190305 CN/NB, revision (a), with validity till January 17, 2024.

Brno, May 23, 2022

Kamil ŠPLÍCHAL
Quality Assurance/Regulatory Affairs
Chief Quality and Regulatory Affairs Officer
(Name, position and signature of authorized person)

Manufacturer´s stamp:

GeneProof®
Molecular diagnostics for your routine
GeneProof a.s., Vídeňská 119, CZ-619 00 Brno
IČ/DIČ: CZ/26981947 / www.geneproof.com